Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
SARS-CoV-2 infection Clinical criteria: The treatment must be for use when nirmatrelvir (&) ritonavir is contraindicated, AND Patient must have received a positive nucleic acid test result; OR Patient must have received a positive rapid antigen test (RAT) result, AND Patient must not require hospitalisation for COVID-19 infection at the time of prescribing, AND The treatment must be initiated within 5 days of symptom onset; OR The treatment must be initiated as soon as possible after a diagnosis is confirmed where asymptomatic. Population criteria: Patient must be at least 70 years of age. Access to this drug through this restriction is permitted irrespective of vaccination status. Where nucleic acid testing is used to confirm diagnosis, the result, testing date, location and test provider must be recorded on the patient record. Where a RAT is used to confirm diagnosis, available information about the test result, testing date, location and test provider (where relevant) must be recorded on the patient record. This drug is not PBS-subsidised for pre-exposure or post-exposure prophylaxis for the prevention of SARS-CoV-2 infection. For the purpose of administering this restriction, the contraindications to nirmatrelvir (&) ritonavir can be found using the Liverpool COVID-19 Drug interaction checker or the TGA-approved Product Information for Paxlovid. Details/reasons of contraindications to nirmatrelvir (&) ritonavir must be documented in the patient's medical records.
“NHC-TP incorporation into viral RNA by the viral RNA polymerase, results in an accumulation of errors in the viral genome leading to inhibition of replication. This mechanism of action is known as viral error catastrophe.”
“The effective half-life of NHC is approximately 3.3 hours.”
“NHC is not a substrate of major drug metabolizing enzymes or transporters. Neither molnupiravir nor NHC are inhibitors or inducers of major drug metabolizing enzymes or transporters.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.